BETA: Please send your feedback!
Seattle Genetics
SGEN:NAS
Biotechnology
—
MID cap
(—)
—
since start of 2020
—
About
Biotechnology
Founded 1997
Seattle Genetics, Inc. engages in the development and commercialization of monoclonal antibody-based therapies for cancer. Its product ADCETRIS, is an antibody-drug conjugate comprising an anti-CD30 monoclonal antibody attached by a protease-cleavable linker to a microtubule disrupting agent, monomethyl auristatin E. The company was founded by Clay B. Siegall and H. Perry Fell on July 15, 1997 and is headquartered in Bothell, WA.
website
Headquarters
Executives
| Name | Title | Gender |
| Jean I. Liu | Executive VP-Legal Affairs & General Counsel | Female |
| Vaughn B. Himes, PhD | Chief Technology Officer | Male |
| Perry Fell, PhD, MBA | Founder | Male |
| Clay B. Siegall, PhD | Chairman, President & Chief Executive Officer | Male |
| Eric L. Dobmeier | Chief Operating Officer | Male |
| Todd E. Simpson, CPA | Chief Financial Officer | Male |
| Jonathan Drachman, MD | Chief Medical Officer, EVP-Research & Development | Male |
| Christopher Pawlowicz | Executive Vice President-Human Resources | Male |
| Elaine Waller, PhD | Executive Vice President-Regulatory Affairs | Female |
| Peggy Pinkston | Executive Director-Investor Relations | Female |
Mindful Investing Summary
Seattle Genetics - Competitors and Related Companies
How Seattle Genetics stacks up to its peers in the Biotechnology industry or with competing business segments.
Seattle Genetics
SGEN:NAS
Biotechnology
—
MID cap
(—)
—
since start of 2020
—
Celldex Therapeutics
CLDX:NAS
Biotechnology
—
SMALL cap
(—)
—
since start of 2020
—
ImmunoGen
IMGN:NAS
Biotechnology
—
SMALL cap
(—)
—
since start of 2020
—
Progenics Pharmaceuticals
PGNX:NAS
Biotechnology
—
SMALL cap
(—)
—
since start of 2020
—
AbbVie
ABBV:NYS
Pharmaceuticals: Major
—
MEGA cap
(—)
—
since start of 2020
—
Bristol-Myers Squibb
BMY:NYS
Pharmaceuticals: Major
—
MEGA cap
(—)
—
since start of 2020
—